-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CB-5339 in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CB-5339 in Myelodysplastic Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CB-5339 in Myelodysplastic Syndrome Drug Details: CB-5339 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CB-5339 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CB-5339 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CB-5339 in Refractory Acute Myeloid Leukemia Drug Details: CB-5339 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CB-5339 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CB-5339 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CB-5339 in Relapsed Acute Myeloid Leukemia Drug Details: CB-5339 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CB-5339 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CB-5339 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.CB-5339 in Relapsed Acute Myeloid Leukemia Drug Details:CB-5339 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CB-5339
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry CB-5339 Drug Details CB-5339 is under development for the treatment of relapsed or refractory...
-
Product Insights
Transitional Endoplasmic Reticulum ATPase (Valosin Containing Protein or 15S Mg(2+) ATPase p97 Subunit or VCP or EC 3.6.4.6) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Transitional Endoplasmic Reticulum ATPase (Valosin Containing Protein or 15S Mg(2+) ATPase p97 Subunit or VCP or EC 3.6.4.6) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Transitional Endoplasmic Reticulum ATPase (Valosin Containing Protein or 15S Mg(2+) ATPase p97 Subunit or VCP or EC 3.6.4.6) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of...
-
Product Insights
Ischemia Reperfusion Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nutrients creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative. Symptoms include headache, bradycardia, seizures, and hypertension. Risk factors include hypertension, hyperlipidemia, diabetes, insulin resistance, heart failure, altered coronary circulation, and aging. The Ischemia Reperfusion Injury drugs in development market research...
-
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) – US Drug Forecast and Market Analysis to 2025
Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted...
-
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) – 5EU Drug Forecast and Market Analysis to 2025
Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted...
-
Sector Analysis
Non-Small Cell Lung Cancer (NSCLC) – Japan Drug Forecast and Market Analysis to 2025
Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted...